长效β受体激动剂福莫特罗与沙丁胺醇起效一样快

长效β受体激动剂福莫特罗与沙丁胺醇起效一样快 长效β受体激动剂福莫特罗与沙丁胺醇 起效一样快 Long-Acting Beta Agonist Formoterol as Rapid as Albuterol By Martha Kerr PHILADELPHIA (Reuters Health) Mar 20 - Bronchodilation is achieved as quickly with the long-acting beta agonist formoterol, given in combination with budesonide (Symbicort, AstraZeneca), as it is when combined with the short-acting beta agonist albuterol, a Texas investigator announced here at the annual meeting of the American Academy of Allergy, Asthma and Immunology, held here this week. The onset of bronchodilation is also more rapid with budesonide/formoterol than with fluticasone/salmeterol (Advair, GlaxoSmithKline). "Formoterol is as quick-acting as albuterol," even though the former is long-acting and the second a fast-acting beta agonist, lead investigator Dr. Frank C. Hampel, Jr., of Central Texas Health Research in New Braunfels told Reuters Health. "The findings are really about the difference between the two different long-acting beta agonists." "Both were significantly quicker to open airways than salmeterol or placebo," he added. The findings come from two four-arm, cross-over treatment studies. Dr. Hampel's team compared onset of bronchodilation among budesonide/formoterol, fluticasone/salmeterol, albuterol and placebo in a total of 109 patients,18 years of age or older with mild-to-moderate asthma. Mean improvements in forced expiratory volume in 1 second (FEV1) 3 minutes after treatment were significantly greater with budesonide/formoterol and albuterol than with fluticasone/salmeterol. All three active treatments were more effective at opening airways than placebo. At least 15% of patients on budesonide/formoterol and at least 12% of patients on albuterol achieved FEV1 within 15 minutes of treatment. All active treatments were well tolerated "This is about the difference in the beta agonist component of the combination drugs," Dr. Hampel said. "We're not going to see fast symptom relief with the corticosteroid component. That's more for prophylaxis." 长效β受体激动剂福莫特罗与沙丁胺醇起效一样快 费城(路透社)3月20日讯一位德州研究人员在本周举行的美国变态反应、 哮喘和免疫学术会议上宣布:布地奈德(Symbicort, 阿斯利康公司生产)联合 长效β受体激动剂福莫特罗使用同它与短效β受体激动剂沙丁胺醇联合时一样 能迅速扩张支气管。 在支气管扩展作用起始时，布地奈德+福莫特罗也比氟替卡松+沙美特罗 (Advair，葛兰素史克公司生产)更迅速。 “福莫特罗像沙丁胺醇一样能快速起效”，纵使前者是长效β受体激动剂 而后者是速效β受体激动剂，在新布朗费尔斯的德州健康研究中心研究者 Frank C. Hampel, Jr博士告诉路透社，“研究发现两种不同长效β受体激动 之间实际上是不同的。” 他补充道“值得注意的是，两者对扩张气道作用都比沙美特罗或对照组更 快，” 这个结论是从二次四臂交叉治疗研究得出的。Hampel博士的医疗队比较了布地奈德+福莫特罗组、氟替卡松+沙美特罗组、沙订氨醇组和对照组，总共109名十八岁以上轻中度哮喘患者支气管扩展起始作用。 在应用治疗3分钟后，一秒用力呼气量(FEV1)的平均改善，布地奈德+福莫特罗组和沙订氨醇组比氟替卡松+沙美特罗组更为明显。所有三个治疗组在扩张气道方面都比对照组更为有效。 在治疗后15分中内FEV1值，布地奈德+福莫特罗组病人至少提高15%，沙 订氨醇组病人至少提高12%。 Hampel博士说，“复方药物组分β受体激动剂是有差异的，我们没有看到皮质类固醇组分能快速缓解症状，更多的则是预防。”